1. Home
  2. MRKR vs PCLA Comparison

MRKR vs PCLA Comparison

Compare MRKR & PCLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • PCLA
  • Stock Information
  • Founded
  • MRKR N/A
  • PCLA 2008
  • Country
  • MRKR United States
  • PCLA Japan
  • Employees
  • MRKR N/A
  • PCLA N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • PCLA Building Products
  • Sector
  • MRKR Health Care
  • PCLA Consumer Discretionary
  • Exchange
  • MRKR Nasdaq
  • PCLA Nasdaq
  • Market Cap
  • MRKR 17.7M
  • PCLA 16.0M
  • IPO Year
  • MRKR N/A
  • PCLA 2025
  • Fundamental
  • Price
  • MRKR $1.35
  • PCLA $0.42
  • Analyst Decision
  • MRKR Strong Buy
  • PCLA
  • Analyst Count
  • MRKR 3
  • PCLA 0
  • Target Price
  • MRKR $13.17
  • PCLA N/A
  • AVG Volume (30 Days)
  • MRKR 3.5M
  • PCLA 3.8M
  • Earning Date
  • MRKR 08-13-2025
  • PCLA 01-01-0001
  • Dividend Yield
  • MRKR N/A
  • PCLA N/A
  • EPS Growth
  • MRKR N/A
  • PCLA N/A
  • EPS
  • MRKR N/A
  • PCLA N/A
  • Revenue
  • MRKR $5,696,123.00
  • PCLA $5,475,228.00
  • Revenue This Year
  • MRKR N/A
  • PCLA N/A
  • Revenue Next Year
  • MRKR $7.16
  • PCLA N/A
  • P/E Ratio
  • MRKR N/A
  • PCLA N/A
  • Revenue Growth
  • MRKR 71.53
  • PCLA 40.19
  • 52 Week Low
  • MRKR $0.95
  • PCLA $0.37
  • 52 Week High
  • MRKR $5.95
  • PCLA $9.80
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 40.86
  • PCLA N/A
  • Support Level
  • MRKR $1.41
  • PCLA N/A
  • Resistance Level
  • MRKR $1.61
  • PCLA N/A
  • Average True Range (ATR)
  • MRKR 0.31
  • PCLA 0.00
  • MACD
  • MRKR -0.04
  • PCLA 0.00
  • Stochastic Oscillator
  • MRKR 2.15
  • PCLA 0.00

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

About PCLA PicoCELA Inc. American Depositary Shares

PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.

Share on Social Networks: